Nasopharyngeal carcinoma medical therapy: Difference between revisions

	Nasopharyngeal carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Nasopharyngeal carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Nasopharyngeal carcinoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Nasopharyngeal carcinoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Nasopharyngeal carcinoma medical therapy
CDC on Nasopharyngeal carcinoma medical therapy
Nasopharyngeal carcinoma medical therapy in the news
Blogs on Nasopharyngeal carcinoma medical therapy
Directions to Hospitals Treating Nasopharyngeal carcinoma
Risk calculators and risk factors for Nasopharyngeal carcinoma medical therapy

Revision as of 12:25, 24 September 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]

The mainstay of therapy for nasopharyngeal carcinoma is external beam radiotherapy, supplemented in some cases with chemotherapy.

The mainstay of therapy for nasopharyngeal carcinoma is external beam radiotherapy

Standard treatments for patients with nasopharyngeal carcinoma include:^[1]
- External beamradiation therapy alone
- Concurrent chemoradiation followed by adjuvant chemotherapy
- Chemotherapy alone for metastatic disease
Undifferentiated subtype of nasopharyngeal carcinoma is highly radiosensitive

@@ Line 12: / Line 12: @@
 **Concurrent chemoradiation followed by adjuvant chemotherapy
 **Chemotherapy alone for [[metastatic]] disease
-*Treatments under clinical evaluation for patients with [[nasopharyngeal cancer]] include the following:<ref name="pmid10571198">{{cite journal| author=Tate DJ, Adler JR, Chang SD, Marquez S, Eulau SM, Fee WE et al.| title=Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: impact on local control. | journal=Int J Radiat Oncol Biol Phys | year= 1999 | volume= 45 | issue= 4 | pages= 915-21 | pmid=10571198 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10571198  }} </ref>
-**Dose escalation with new radiation therapy techniques such as stereotactic radiation therapy boost
-**[[Brachytherapy]]
 *Undifferentiated subtype of nasopharyngeal carcinoma is highly radiosensitive